MARKET

ALPN

ALPN

Alpine Immune
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.18
+0.68
+9.07%
Closed 16:00 09/25 EDT
OPEN
7.64
PREV CLOSE
7.50
HIGH
8.27
LOW
7.59
VOLUME
38.47K
TURNOVER
--
52 WEEK HIGH
15.00
52 WEEK LOW
2.050
MARKET CAP
194.56M
P/E (TTM)
-4.5971
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Alpine Immune Sciences to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Alpine Immune Sciences to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Business Wire · 09/15 20:05
Alpine Immune Sciences to Present at H.C. Wainwright 22nd Annual Global Investment Conference
Alpine Immune Sciences to Present at H.C. Wainwright 22nd Annual Global Investment Conference
Business Wire · 09/08 20:05
New Strong Sell Stocks for September 8th
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today.
Zacks · 09/08 13:57
Benzinga's Top Upgrades, Downgrades For August 26, 2020
Upgrades * Evercore ISI Group upgraded the previous rating for The Hain Celestial Group Inc (NASDAQ: HAIN) from In-Line to Outperform. In the fourth quarter, Hain Celestial Group showed an EPS of $0.32, compared to $0.21 from the year-ago quarter. The stock has a 52-week-high of $34.53 and a 52-week-low
Benzinga · 08/26 13:42
Alpine Immune Sciences Q2 EPS $(0.53) Up From $(0.64) YoY, Sales $688.00K Up From $567.00K YoY
Alpine Immune Sciences (NASDAQ:ALPN) reported quarterly losses of $(0.53) per share. This is a 17.19 percent increase over losses of $(0.64) per share from the same period last year. The company reported $688.00
Benzinga · 08/11 20:19
Alpine Immune Sciences to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference
Alpine Immune Sciences to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference
Business Wire · 08/05 20:05
Alpine Immune Sciences to Report Second Quarter 2020 Financial Results and Provide Corporate Update
Alpine Immune Sciences to Report Second Quarter 2020 Financial Results and Provide Corporate Update
Business Wire · 08/04 20:05
Alpine Immune Sciences secures equity capital of $60M
Seeking Alpha · 07/24 13:46
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ALPN. Analyze the recent business situations of Alpine Immune through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ALPN stock price target is 21.50 with a high estimate of 27.00 and a low estimate of 18.00.
EPS
Institutional Holdings
Institutions: 32
Institutional Holdings: 8.53M
% Owned: 35.84%
Shares Outstanding: 23.78M
TypeInstitutionsShares
Increased
5
106.27K
New
13
-1.01M
Decreased
2
122.59K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.04%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
Chairman/Chief Executive Officer/Chief Compliance Officer/Executive Director
Mitchell Gold
President
Stanford Peng
Chief Financial Officer/Senior Vice President/Secretary
Paul Rickey
Chief Technology Officer
Wayne Gombotz
Director
Jay Venkatesan
Independent Director
Robert Conway
Independent Director
Min Cui
Independent Director
Xiangmin Cui
Independent Director
Christopher Peetz
Independent Director
Paul Sekhri
Independent Director
Peter Thompson
Independent Director
James Topper
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ALPN
Alpine Immune Sciences, Inc., formerly Nivalis Therapeutics, Inc., is focused on developing a protein-based immunotherapies using Variant immunoglobulin domain (vlgD) platform technology. The vlgD platform is designed to interact with multiple targets, including many present in the immune synapse. The vlgDs are developed using a process known as directed evolution. The vlgD platform exploits both known and unknown interactions at immune synapse through a process called direct evolution for patients living with cancer, autominnue/inflammatory conditions and chronic infectious disease. It optimizes native immune system proteins for use as therapeutics. The Company also developed Transmembrane Immunomodulatory Protien (TIP) technology, based on the vIgD platform, to enhance engineered cellular therapies. TIP program is created to help companies focused on engineered cellular therapies.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Alpine Immune Sciences Inc stock information, including NASDAQ:ALPN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALPN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALPN stock methods without spending real money on the virtual paper trading platform.